The investigation builds off the larger IDEAS Study and will include at least 4,000 Black and Hispanic patients out of the estimated 7,000 total participants.

The stock purchase deal also includes a long-term supply agreement, which is subject to customary closing conditions and expected to wrap-up in the first quarter of next year.

Both the University of California, San Francisco, and UCLA received the greenlight for Gallium-68 PSMA-11 and noted it is rare for academic institutions to obtain such approval.

The pair said that without hearing a solid argument, they will be "relentless" in opposing the insurance giant's coverage determination. 

The Society of Nuclear Medicine and Molecular Imaging said the move denies patients access to potentially lifesaving technologies.

Alzheimer's Association President and CEO Harry Johns said the vote was disappointing, claiming publicly released data on aducanumab justified its federal approval.

Tokyo-based Astellas's tracer was developed to supplement surgeries and reduces the chance of iatrogenic ureteral injury during colorectal or gynecologic procedures.

The findings were presented virtually at the American Society for Radiation Oncology's Annual Meeting.

In one case, the tracer detected a cerebral abnormality that occurred three years prior to imaging, according to Massachusetts General Hospital researchers.

The quality issue could force more than 12,000 patients into canceled exams.

This update will replace the company’s existing infusion system and includes new smart features, such as workflow improvements and dosing options.

President and CEO Ken Song, MD, said the radiopharmaceutical field remains an untapped opportunity in cancer care.